Ganoderic acid A attenuates high-fat-diet-induced liver injury in rats by regulating the lipid oxidation and liver inflammation.

Abstract

Ganoderic Acid A (GA) has many pharmacological effects such as anti-tumor, antibacterial, anti-inflammatory, and immunosuppressive effects. However, the protective effect of GA on liver injury has not been reported. This study aimed to investigate the action of GA on insufficient methionine and choline combined with high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) in rats. NAFLD model was established by insufficient methionine and choline combined with high fat feeding to rats. The levels of Acetyl-CoA carboxylase, fatty acid synthase, sterol regulatory element binding protein, liver X receptors, AMP-activated protein kinase, peroxisome proliferator-activated receptor α, PPARg coactivator 1α and NF-κB pathway in the liver were detected by western blot. The results of this study demonstrated that the expression of GA can not only significantly decrease the live weight and liver weight per body weight of HFD mice, but also restore the alanine aminotransferase, aspartate aminotransferase, total bilirubin levels, triglyceride and cholesterol in serum. In addition, the expression of GA increased the levels of high-density lipoprotein cholesterol in serum, ameliorated pathological changes and decreased NAS score of mice's liver. In conclusion, the treatment with GA could improve NAFLD in rats by regulating the levels of signaling events involved in free fatty acid production, lipid oxidation and liver inflammation.

• Authors: Fuli Liu, Kejian Shi, Jiaojiao Dong, Zhousheng Jin, Yiquan Wu, Yaoyao Cai, Tingting Lin, Qianqian Cai, Le Liu, Yujian Zhang
• Journal: Archives of pharmacal research (Arch Pharm Res) Vol. 43 Issue 7 Pg. 744-754 (Jul 2020) ISSN: 1976-3786 [Electronic] Korea (South)
• PMID: 32715385 (Publication Type: Journal Article)

Chemical References

• Cytokines
• Heptanoic Acids
• Protective Agents
• Lanosterol
• ganoderic acid A

Topics

• Administration, Oral
• Animals
• Cytokines (antagonists & inhibitors, blood, metabolism)
• Diet, High-Fat (adverse effects)
• Heptanoic Acids (administration & dosage, pharmacology)
• Inflammation (chemically induced, drug therapy, metabolism)
• Lanosterol (administration & dosage, analogs & derivatives, pharmacology)
• Lipid Metabolism (drug effects)
• Male
• Non-alcoholic Fatty Liver Disease (chemically induced, drug therapy, metabolism)
• Protective Agents (administration & dosage, pharmacology)
• Rats
• Rats, Sprague-Dawley